Author Affiliations: Institute for Healthcare Improvement, Cambridge, Massachusetts (Drs Sullivan and Goldmann); and Department of Pediatrics, Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts (Dr Goldmann). Dr Sullivan is now with the Department of Quality Improvement, Salford Royal Foundation Trust, Salford, England.
The American Recovery and Reinvestment Act will provide an unprecedented stimulus for translational and health services research. A $1.1 billion investment in comparative effectiveness research (CER)1 should produce a torrent of new information about the effectiveness of drugs, technologies, and interventions. For this to result in better, more cost-effective health care, better evidence is needed to address the translational gap between clinical studies and everyday practice.2 In essence, this is CER for implementation strategies (a type of CER seriously underrepresented in current discourse, but necessary to deliver on the Institute of Medicine's goals for improved health care quality).
Sullivan P, Goldmann D. The Promise of Comparative Effectiveness Research. JAMA. 2011;305(4):400-401. doi:10.1001/jama.2011.12